Pediatric Infection and Vaccine

  • 제20권3호
  • /
  • Pages.131-138
  • /
  • 2013
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지

일본뇌염 예방접종 후 면역원성 및 중화항체 지속률에 관한 조사: 전향적 다기관 코호트 연구

Immunogenicity and Protective Effectiveness of Japanese Encephalitis Vaccine: A Prospective Multicenter Cohort Study

  • 김동현 (인하대학교 의학전문대학원 소아과학교실) ;
  • 홍영진 (인하대학교 의학전문대학원 소아과학교실) ;
  • 이훈재 (인하대학교 의학전문대학원 사회의학교실) ;
  • 최보율 (한양대학교 의과대학 예방의학교실) ;
  • 김창휘 (순천향대학교 의과대학 소아과학교실) ;
  • 박재옥 (순천향대학교 의과대학 소아과학교실) ;
  • 강진한 (가톨릭대학교 의과대학 소아과학교실) ;
  • 최병준 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김종현 (가톨릭대학교 의과대학 소아과학교실) ;
  • 안영민 (을지대학교 의과대학 소아과학교실) ;
  • 주영란 (국립보건연구원 신경계 바이러스과) ;
  • 정영의 (국립보건연구원 신경계 바이러스과) ;
  • 한명국 (국립보건연구원 신경계 바이러스과)
  • Kim, Dong Hyun (Department of Pediatrics, Inha University Shool of Medicine) ;
  • Hong, Young-Jin (Department of Pediatrics, Inha University Shool of Medicine) ;
  • Lee, Hoon-Jai (Department of Social Medicine, Inha University School of Medicine) ;
  • Choi, Bo-Yul (Department of Preventive Medicine, Hanyang University Medical School) ;
  • Kim, Chang Hwi (Department of Pediatrics, Soonchunhyang University College of Medicine) ;
  • Park, Jae Ock (Department of Pediatrics, Soonchunhyang University College of Medicine) ;
  • Kang, Jin Han (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Choi, Byung Joon (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Jong Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Ahn, Young Min (Department of Pediatrics, Eulji University School of Medicine) ;
  • Ju, Young Ran (Division of Arbovirus, Center for Immunology and Pathology, Korea National Institute of Health) ;
  • Jeong, Young Eui (Division of Arbovirus, Center for Immunology and Pathology, Korea National Institute of Health) ;
  • Han, Myung Guk (Division of Arbovirus, Center for Immunology and Pathology, Korea National Institute of Health)
  • 투고 : 2013.05.02
  • 심사 : 2013.05.30
  • 발행 : 2013.12.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 일본뇌염 백신의 면역원성 및 중화항체 지속률을 평가하여 일본뇌염 예방 사업을 위한 토대를 제공하고자 하였다. 방법: 국내 6개 대학병원에 입원한 2-6세의 어린이 중 기초접종력이 확인된 170명을 대상으로 기초접종 완료 경과 기간에 따른 중화항체가를 조사하였다. 결과: 총 170명 중 불활성화 백신 접종군 103명, 생백신 접종군 64명, 교차접종군 3명이었다. 항체검사까지의 기간은 불활성화 백신 17.5개월, 생백신 21.0개월이었고 모두 일본뇌염 방어가 가능한 항체가를 보여 불활성화 백신 322, 생백신 266이었다. 추가접종 후 항체역가 변화는 1-4개월에 가장 높았고 이후 서서히 떨어지는 경향을 보였다. 결론: 불활성화 백신과 생백신의 면역원성과 중화항체 지속률에는 차이가 없고 두 백신 모두 일본뇌염 예방을 위한 적절한 수준의 면역원성을 갖고 있었다. 향후 대규모 표본을 대상으로 더 많은 연구가 필요하다.

Purpose: This study aimed to study the antibody response of Japanese encephalitis vaccination in children using different kinds of vaccines (inactivated vaccine, live attenuated vaccine or interchanged) and evaluate the effectiveness of the vaccines to provide the basis of efficient immunization schedule of Japanese encephalitis. Methods: Measurement of the neutralization antibody (NTAb) titers following Japanese encephalitis vaccination using different vaccines for 170 children, 2-6 year of age, who visited six university hospitals and are confirmed by immunization records. Results: Among 170 children who were given primary immunization on Japanese encephalitis, 103 children were given inactivated vaccine, 64 children were given live attenuated vaccine and 3 children were given interchangeably. NTAb titers were more than 1:10 in all children of three groups. The geographic mean antibody titer was 322 in inactivated vaccine group and 266 in live attenuated vaccine group. However, there was no significant difference between two groups. In both groups, the NTAb titer showed the peak at 1-4 months after the third immunization and declined. The NTAb titers of three children who were given two kinds of vaccines alternately were 1:135, 1:632, and 1:2511, respectively. Conclusion: According to the results of this study in children younger than 6 years old, there is no significant difference in effectiveness between inactivated and live attenuated vaccines. However, further studies for the changes of antibody titers for a longer period of time on larger population are required.

키워드

참고문헌

  1. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990;44:649-88. https://doi.org/10.1146/annurev.mi.44.100190.003245
  2. Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg Infect Dis 2009;15:1-7. https://doi.org/10.3201/eid1501.080311
  3. Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol 2002;267:11-48.
  4. Halstead SB, Jacobson J, Dubischar-Kastner. Japanese encephalitis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Elsevier Saunders Co, 2013:312-51.
  5. Department of Health. Japanese encephalitis. In: Salisbury D, Ramsay M, Noakes K, editors. Immunisation against infectious disease. 3rd ed. London: TSO Co, 2013:201-8.
  6. Hong YJ. The Japanese encephalitis vaccine: worldwide and korean status. Korean J Pediatr Infect Dis 2008;15:108-14.
  7. Sohn YM. The background and changes of inactivated Japanese encephalitis vaccine schedule. Korean J Pediatr Infect Dis 2000;7:56-70.
  8. Calisher CH, Monath TP. Togaviridae and Flaviviridae: the alphaviruses and Flaviviruses. In: Lennette EH, Halonen P, Murphy FA, editors. Laboratory diagnosis of infectious diseases. 2nd ed. New York: Springer-Verlag,1988:414-34.
  9. Korea Center for Disease Control and Prevention. Japanese encephalitis in Korea since 2001. Public Health Weekly Report 2008;1:289-92.
  10. Korea Center for Disease Control and Prevention. Activity of Japanese encephalitis virus in the Republic of Korea 2012 [Internet]. Osong: Division of Arbovirus; c2013 [Cited 2013 Apr 25]. Available from: http://www.cdc. go.kr/CDC/cms/cmsFileDownload.jsp?fid=31&cid=20 762&fieldName=attach1&index=1
  11. Hsu TC, Chow LP, Wei HY, Chen CL, Hsu ST. A completed field trial for an evaluation of the effectiveness of mouse-brain Japanese encephalitis vaccine. In: Hammon WMcD, Kitaoka M, Downs WG, editors. Immunization for Japanese Encephalitis. Amsterdam: Excerpta Medica 1972:285-91.
  12. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. N Eng J Med 1988;319:608-14. https://doi.org/10.1056/NEJM198809083191004
  13. Yang SE, Pan MJ, Tseng HF, Liau MY. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine-results from 30 years experience in Taiwan. Vaccine 2006;24:2669-73. https://doi.org/10.1016/j.vaccine.2005.10.054
  14. Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis 1990;161:878-82. https://doi.org/10.1093/infdis/161.5.878
  15. Sohn YM, Pyun BY, Lee HJ, Kang JH, Hong YJ, Oh SH, et al. Report of study result regarding effective level of antibody persistence rate after Japanese B encephalitis vaccination. Korean J Pediatr 1995;38:730-1.
  16. Oya A. Japanese encephalitis vaccine. Acta Paediatr Jpn 1988;30:175-84. https://doi.org/10.1111/j.1442-200X.1988.tb02516.x
  17. Aihara H, Takasaki T, Matsutani T, Suzuki R, Kurane I. Establishment and characterization of Japanese encephalitis virus-specific, human CD4(+) T-cell clones: flavivirus cross-reactivity, protein recognition, and cytotoxic activity. J Virol 1998;72:8032-6.
  18. Van der Vliet D, Simon de Fanti A, Murri S, Lapidus N, Goujon C, Zeller H, et al. Long-term seroprotection against Japanese encephalitis using an inactivated vaccine (Jevax). Med Trop (Mars) 2010;70:155-7.
  19. Ku CC, King CC, Lin CY, Hsu HC, Chen LY, Yueh YY, et al. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. J Med Virol 1994;44:122-31. https://doi.org/10.1002/jmv.1890440204
  20. Hennessy S, Liu Z, Tsai TF, Strom BL, Wan CM, Liu HL, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA 14-14-2): a case-control study. Lancet 1996;347:1583-6. https://doi.org/10.1016/S0140-6736(96)91075-2
  21. Sohn YM, Park MS, Rho HO, Chandler LJ, Shope RE, Tsai TF. Primary and booster immune responses to SA 14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine 1999;17:2259-64. https://doi.org/10.1016/S0264-410X(99)00006-7